Amoy Diagnostics Co Ltd
SZSE:300685
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.78
27.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Amoy Diagnostics Co Ltd
Amoy Diagnostics Co Ltd
Net Income (Common)
Amoy Diagnostics Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amoy Diagnostics Co Ltd
SZSE:300685
|
Net Income (Common)
¥315m
|
CAGR 3-Years
11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-¥6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
¥1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Net Income (Common)
¥1.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Income (Common)
¥6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
26%
|
CAGR 10-Years
48%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Net Income (Common)
¥1.9B
|
CAGR 3-Years
62%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
Amoy Diagnostics Co Ltd
Glance View
Amoy Diagnostics Co., Ltd. engages in the research, development, production and sale of tumour precision medical molecular diagnostic products. The company is headquartered in Xiamen, Fujian and currently employs 1,096 full-time employees. The company went IPO on 2017-08-02. The firm provides testing reagents and testing services for tumor diagnosis. The Company’s testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The firm also provides data software to capture and analyze gene sequencing data. The firm provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.
See Also
What is Amoy Diagnostics Co Ltd's Net Income (Common)?
Net Income (Common)
315m
CNY
Based on the financial report for Sep 30, 2024, Amoy Diagnostics Co Ltd's Net Income (Common) amounts to 315m CNY.
What is Amoy Diagnostics Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
18%
Over the last year, the Net Income (Common) growth was 48%. The average annual Net Income (Common) growth rates for Amoy Diagnostics Co Ltd have been 11% over the past three years , 18% over the past five years .
You don't have any saved screeners yet
